| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/24/2011 | US20110071093 Novel Reagents |
| 03/24/2011 | US20110071090 Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle |
| 03/24/2011 | US20110071087 Polypeptides having modulatory effects on cells |
| 03/24/2011 | US20110071085 Use of survivin to treat kidney failure |
| 03/24/2011 | US20110071084 Benzazepine derivatives useful as vasopressin antagonists |
| 03/24/2011 | US20110071081 Methods useful in the treatment of bone resorption diseases |
| 03/24/2011 | US20110071080 Methods and compositions for sleep disorders and other disorders |
| 03/24/2011 | US20110071075 Promoter for bicarbonate secretion in gastrointestinal tract |
| 03/24/2011 | US20110071071 Psmb10: a diagnosis marker and therapeutic target of chronic rejection |
| 03/24/2011 | US20110070575 Immunomodulatory Compositions, Combinations and Methods |
| 03/24/2011 | US20110070319 Bifeprunox doses for treating schizophrenia |
| 03/24/2011 | US20110070317 Pyrrolopyridines as kinase inhibitors |
| 03/24/2011 | US20110070316 Antimicrobial Compositions Containing Synergistic Combinations of Quaternary Ammonium Compounds and Essential Oils and/or Constituents Thereof |
| 03/24/2011 | US20110070310 Topical ophthalmic pharmaceutical formulation of (2s,3s,4r)-n''-cyano-n-(6-amino-3,4-dihydro-3-hydroxy-2-methyl-2-dimethoxymethyl-2h-benzopyran-4-yl)-n'-benzylguanidine |
| 03/24/2011 | US20110070309 Pharmaceutical formulation comprising a water-insoluble active agent |
| 03/24/2011 | US20110070306 Antimicrobial nanoemulsion compositions and methods |
| 03/24/2011 | US20110070305 Sustained release pharmaceutical composition containing mebicar |
| 03/24/2011 | US20110070303 Novel dosage formulation |
| 03/24/2011 | US20110070302 Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release |
| 03/24/2011 | US20110070301 Orally transformable tablets |
| 03/24/2011 | US20110070300 Extended release dosage forms of metoprolol |
| 03/24/2011 | US20110070299 Delayed release pharmaceutical composition of duloxetine |
| 03/24/2011 | US20110070297 Glucokinase activators |
| 03/24/2011 | US20110070295 Methods for the preparation of liposomes comprising docetaxel |
| 03/24/2011 | US20110070294 Methods for the Administration of Drugs Using Liposomes |
| 03/24/2011 | US20110070293 Methods for the Preparation of Liposomes Comprising Docetaxel |
| 03/24/2011 | US20110070292 Methods For The Preparation Of Liposomes |
| 03/24/2011 | US20110070291 Food or beverage composition fortified with thyronamines and/or thyronamine precursors |
| 03/24/2011 | US20110070289 Adaptable modified virus vector to deliver modified messenger ribonucleic acid as a medical treatment device to manage diabetes mellitus and other protein deficient diseases |
| 03/24/2011 | US20110070287 Film-Coated Compressed Chewing Gum |
| 03/24/2011 | US20110070285 Method of making flexible bioresorbable hemostatic packing and stent having a preselectable in-vivo residence time |
| 03/24/2011 | US20110070284 Biologic matrices comprising anti-infective methods and compositions related thereto |
| 03/24/2011 | US20110070274 Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide |
| 03/24/2011 | US20110070272 Materials and Methods for Modulating Metabolism |
| 03/24/2011 | US20110070270 Immunostimulating agent |
| 03/24/2011 | US20110070269 Lipopolysaccharide isolated from pyrularia tissue and/or pyrularia-associated bacteria and uses thereof |
| 03/24/2011 | US20110070258 Method of slowing the aging process by activating sirtuin enzymes |
| 03/24/2011 | US20110070253 Tumour-associated peptides binding to mhc molecules |
| 03/24/2011 | US20110070245 Imp-1 oncogene as a therapeutic target and prognostic indicator for lung cancer |
| 03/24/2011 | US20110070244 Methods for the treatment of multiple myeloma |
| 03/24/2011 | US20110070242 Methods for Diagnosing and Treating Iron Dysregulation |
| 03/24/2011 | US20110070240 Methods of treating b-cell cancers |
| 03/24/2011 | US20110070237 Methods of modulating and identifying agents that modulate intracellular calcium |
| 03/24/2011 | US20110070234 Np1 activity regulating elements useful for the production of drugs for the treatment or prevention of human neurodegenerative diseases, resulting drugs and use thereof |
| 03/24/2011 | US20110070232 Combination Therapy with an Antitumor Alkaloid |
| 03/24/2011 | US20110070224 Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
| 03/24/2011 | US20110070221 Gnaq mutations in melanoma |
| 03/24/2011 | US20110070220 Immunomodulating gene therapy |
| 03/24/2011 | US20110070218 Methods of treating cancer of the central nervous system |
| 03/24/2011 | US20110070213 Dermal compositions containing coenzyme q as the active ingredient |
| 03/24/2011 | US20110070199 Adaptable modified virus vector to deliver ribosomal ribonucleic acid combined with messenger ribonucleic acid as a medical treatment device to manage diabetes mellitus and other protein deficient dieases |
| 03/24/2011 | US20110070197 Hepatitis c virus inhibitors |
| 03/24/2011 | US20110070196 Hepatitis c virus inhibitors |
| 03/24/2011 | US20110070194 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| 03/24/2011 | US20110070193 Anti-Infective Agents and Uses Thereof |
| 03/24/2011 | US20110070192 Method of preparation of novel nucleoside analogs and uses |
| 03/24/2011 | US20110070190 Heterocyclic antiviral compounds |
| 03/24/2011 | US20110070189 Heterocyclic antiviral compounds |
| 03/24/2011 | US20110070188 Bab triblock polymers having improved release characteristics |
| 03/24/2011 | US20110070187 Methods for the Preparation of HCV Polymerase Inhibitors |
| 03/24/2011 | US20110070176 Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid |
| 03/24/2011 | US20110070171 1-tert-Butylcyclohexanecarboxamide and uses thereof as cooling compounds |
| 03/24/2011 | US20110070169 Effervescent Oral Fentanyl Dosage Form and Methods of Administering Fentanyl |
| 03/24/2011 | US20110070167 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
| 03/24/2011 | US20110070162 Rna interference mediating small rna molecules |
| 03/24/2011 | US20110070159 Compositions comprising red microalgae polysaccharides and metals |
| 03/24/2011 | DE102010044516A1 Hemmung des Überlebens von Lymphom durch Cyclohexenonverbindungen aus Antrodia camphorata Inhibition of survival of lymphoma cyclohexenone from Antrodia camphorata by |
| 03/24/2011 | DE102009041839A1 Preparation of a donepezil-containing tablet, useful for treating mild to moderate dementia of the Alzheimer type, comprises wet granulation of donepezil with granulating liquid and excipients e.g. cellulose and starch |
| 03/24/2011 | DE102009041048A1 Topically applicable pharmaceutical composition, useful for treating skin diseases e.g. actinic keratosis, comprises a frankincense extract or a frankincense active material and hyaluronic acid or its derivatives |
| 03/24/2011 | DE102009029630A1 Antimikrobielle Amide Antimicrobial amides |
| 03/24/2011 | CA2838352A1 Novel heparin entities and methods of use |
| 03/24/2011 | CA2812158A1 Bisphosphonate-prostatic acid phosphatase inhibitor conjugates to treat prostate cancer bone metastasis |
| 03/24/2011 | CA2774981A1 O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators |
| 03/24/2011 | CA2774796A1 Contact lens disinfecting solutions |
| 03/24/2011 | CA2774772A1 Compositions and methods for treating bacterial infections using ceftaroline |
| 03/24/2011 | CA2774645A1 Pharmaceutical composition for peroral administration of 3,3'-diindolylmethane |
| 03/24/2011 | CA2774550A1 Use of the sparc microenvironment signature in the treatment of cancer |
| 03/24/2011 | CA2774515A1 Substituted phenylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same |
| 03/24/2011 | CA2774486A1 Na/k-atpase ligands, ouabain antagonists, assays and uses thereof |
| 03/24/2011 | CA2774460A1 Inhibition of endosomal toll-like receptor activation |
| 03/24/2011 | CA2774451A1 Dietary supplement stimulating the male sexual function |
| 03/24/2011 | CA2774375A1 Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
| 03/24/2011 | CA2774374A1 Substituted benzamide analogs as mglur5 negative allosteric modulators and methods of making and using the same |
| 03/24/2011 | CA2774373A1 Substituted heteroarylamide analogs as mglur5 negative allosteric modulators and methods of making and using the same |
| 03/24/2011 | CA2774372A1 Substituted heteroarylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same |
| 03/24/2011 | CA2774367A1 Novel compounds and therapeutic use thereof for protein kinase inhibition |
| 03/24/2011 | CA2774359A1 Compositions and methods for treating seizure disorders |
| 03/24/2011 | CA2774357A1 Compositions and methods for treating disorders of gastrointestinal motility |
| 03/24/2011 | CA2774356A1 Combination and composition that contains an antimicrobial, a glucocorticoid and an antimycotic |
| 03/24/2011 | CA2774355A1 Compositions and methods for treating spasticity |
| 03/24/2011 | CA2774327A1 Pharmaceutical compositions which inhibit fkbp52-mediated regulation of androgen receptor function and methods of using same |
| 03/24/2011 | CA2774266A1 Novel tricyclic protein kinase modulators |
| 03/24/2011 | CA2774264A1 Improved device and method for delivery of a medicament |
| 03/24/2011 | CA2774239A1 Treatment for oxidative stress and/or hypertension |
| 03/24/2011 | CA2774220A1 Nasal, wound and skin formulations and methods for control of antibiotic-resistant staphylococci and other gram-positive bacteria |
| 03/24/2011 | CA2774168A1 Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle |
| 03/24/2011 | CA2774149A1 Lubiprostone for obstetrical or gynecological applications |
| 03/24/2011 | CA2774148A1 Tricyclic compounds and pharmaceutical uses thereof |
| 03/24/2011 | CA2774145A1 Hcv protease inhibitors |
| 03/24/2011 | CA2774021A1 Use of opioid receptor antagonist for gastrointestinal tract disorders |